BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias.

RESULTS: We show here that the SH3 domain of p85alpha (p85alpha-SH3) pulls down the p210BCR/ABL kinase from hematopoietic cell lysates.

[MeSH-minor] Amino Acid Substitution. Animals. Cell Line, Tumor. Fusion Proteins, bcr-abl. Hematopoietic Stem Cells / metabolism. Humans. Immunoprecipitation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Mice. Mutagenesis, Site-Directed. Point Mutation / genetics. Protein Binding

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16219545.001).

[ISSN] 0301-472X

[Journal-full-title] Experimental hematology

[ISO-abbreviation] Exp. Hematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA83700

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Protein Subunits; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Human SCID (Severe Combined Immunodeficiency) is a prenatal disorder of T lymphocyte development, that depends on the expression of numerous genes.

The knowledge of the genetic basis of SCID is essential for diagnosis (e.g., clinical phenotype, lymphocyte profile) and treatment (e.g., use and type of pre-hematopoietic stem cell transplant conditioning).Over the last years novel genetic defects causing SCID have been discovered, and the molecular and immunological mechanisms of SCID have been better characterized.

Distinct forms of SCID show both common and peculiar (e.g., absence or presence of nonimmunological features) aspects, and they are currently classified into six groups according to prevalent pathophysiological mechanisms: impaired cytokine-mediated signaling; pre-T cell receptor defects; increased lymphocyte apoptosis; defects in thymus embryogenesis; impaired calcium flux; other mechanisms.This review is the updated, extended and largely modified translation of the article "Cossu F: Le basi genetiche delle SCID", originally published in Italian language in the journal "Prospettive in Pediatria" 2009, 156:228-238.

[MeSH-minor] Genetic Therapy. Genotype. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Neonatal Screening. T-Lymphocytes / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Pediatr. 2005 Jan;146(1):137-40 [15644840.001]

[Cites] Immunol Rev. 2005 Feb;203:110-26 [15661025.001]

[Cites] Immunol Rev. 2005 Feb;203:127-42 [15661026.001]

[Cites] Bone Marrow Transplant. 2005 Mar;35(6):537-47 [15665844.001]

[Cites] Blood. 2005 Jun 1;105(11):4179-86 [15731174.001]

[Cites] J Clin Invest. 2005 Nov;115(11):2974-6 [16276411.001]

[Cites] Mol Genet Metab. 2005 Dec;86(4):427-30 [16260163.001]

[Cites] J Immunol. 2002 Jun 15;168(12):6323-9 [12055248.001]

[Cites] Br J Haematol. 2002 Dec;119(3):765-8 [12437656.001]

[Cites] Nat Rev Cancer. 2003 Jul;3(7):477-88 [12835668.001]

[Cites] J Allergy Clin Immunol. 2004 Apr;113(4):734-41 [15100681.001]

[Cites] Ann Hum Genet. 2004 May;68(Pt 3):265-8 [15180707.001]

[Cites] Lancet. 2004 Jun 19;363(9426):2051-4 [15207958.001]

[Cites] Pediatr Res. 1977 Jan;11(1 Pt 2):63-89 [401538.001]

[Cites] Pediatr Res. 1984 Aug;18(8):723-8 [6332299.001]

[Cites] N Engl J Med. 1985 May 2;312(18):1151-9 [2984567.001]

[Cites] Cell. 1993 Apr 9;73(1):147-57 [8462096.001]

[Cites] J Allergy Clin Immunol. 1994 Feb;93(2):543-50 [8120281.001]

[Cites] Am J Med Genet. 1996 Oct 16;65(2):167-70 [8911612.001]

[Cites] J Pediatr. 1997 Mar;130(3):345-6 [9063405.001]

[Cites] J Pediatr Hematol Oncol. 2006 Jan;28(1):53-6 [16394896.001]

[Cites] Cell. 2006 Jan 27;124(2):287-99 [16439204.001]

[Cites] J Pediatr. 2006 Feb;148(2):272-4 [16492442.001]

[Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]

[Cites] J Allergy Clin Immunol. 2006 Apr;117(4):897-903 [16630949.001]

[Cites] Nat Rev Immunol. 2006 Oct;6(10):728-40 [16998507.001]

[Cites] Orphanet J Rare Dis. 2006;1:34 [16959034.001]

[Cites] Hum Mutat. 2006 Dec;27(12):1174-84 [16960852.001]

[Cites] Nat Genet. 2007 Jan;39(1):86-92 [17187068.001]

[Cites] J Immunol. 2007 Feb 15;178(4):2556-64 [17277165.001]

[Cites] Blood. 2007 Apr 15;109(8):3198-206 [17170122.001]

[Cites] Blood. 2007 Apr 15;109(8):3595-602 [17185467.001]

[Cites] J Allergy Clin Immunol. 2007 Aug;120(2):423-8 [17481714.001]

[Cites] Nat Rev Immunol. 2007 Sep;7(9):690-702 [17703229.001]

[Cites] Lancet. 2007 Oct 20;370(9596):1443-52 [17950858.001]

[Cites] J Obstet Gynaecol Can. 2007 Nov;29(11):927-44 [17977497.001]

[Cites] J Clin Invest. 1998 Jul 15;102(2):421-9 [9664084.001]

[Cites] Clin Genet. 2008 Apr;73(4):380-4 [18339010.001]

[Cites] Annu Rev Immunol. 2008;26:355-88 [18304000.001]

[Cites] Annu Rev Immunol. 2008;26:233-59 [18304005.001]

[Cites] J Allergy Clin Immunol. 2008 Apr;121(4):1056-8 [18243287.001]

[Cites] Blood. 2008 Apr 15;111(8):4209-19 [18218852.001]

[Cites] Clin Exp Immunol. 2008 Jul;153(1):75-80 [18505430.001]

[Cites] Nat Rev Immunol. 2008 Jul;8(7):545-58 [18551129.001]

[Cites] J Clin Invest. 2008 Sep;118(9):3143-50 [18688286.001]

[Cites] Nat Immunol. 2008 Nov;9(11):1307-15 [18836449.001]

[Cites] J Immunol. 2008 Nov 1;181(9):5815-6 [18941168.001]

[Cites] Blood. 2008 Nov 1;112(9):3594-600 [18669893.001]

[Cites] Curr Opin Allergy Clin Immunol. 2008 Dec;8(6):510-4 [18978464.001]

[Cites] Curr Opin Allergy Clin Immunol. 2008 Dec;8(6):534-9 [18978468.001]

[Cites] Eur J Pediatr. 2009 Jan;168(1):87-93 [18509675.001]

[Cites] Science. 2008 Dec 5;322(5907):1562-5 [19056990.001]

[Cites] J Allergy Clin Immunol. 2008 Dec;122(6):1219-20 [18845326.001]

[Cites] J Allergy Clin Immunol. 2008 Dec;122(6):1082-6 [18992930.001]

[Cites] Nat Genet. 2009 Jan;41(1):106-11 [19043416.001]

[Cites] Nat Genet. 2009 Jan;41(1):101-5 [19043417.001]

[Cites] J Inherit Metab Dis. 2009 Aug;32(4):459-71 [19585268.001]

[Cites] Adv Exp Med Biol. 2009;650:46-58 [19731800.001]

[Cites] Immunol Res. 2009;45(1):37-45 [19238335.001]

[Cites] Blood. 2009 Oct 8;114(15):3216-26 [19633200.001]

[Cites] Blood. 2009 Oct 22;114(17):3524-32 [19638621.001]

[Cites] Nat Rev Immunol. 2009 Nov;9(11):811-6 [19809471.001]

[Cites] Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):496-502 [19779332.001]

[Cites] Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):503-9 [19823081.001]

[Cites] Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):489-95 [19841578.001]

[Cites] Clin Immunol. 2009 Dec;133(3):287-94 [19740703.001]

[Cites] Pediatrics. 2000 Mar;105(3):E39 [10699141.001]

[Cites] Int Immunol. 2000 Apr;12(4):449-57 [10744646.001]

[Cites] Curr Opin Immunol. 2000 Aug;12(4):468-73 [10899029.001]

[Cites] J Immunol. 2001 Jan 15;166(2):1308-13 [11145714.001]

[Cites] Bone Marrow Transplant. 2001 Aug;28(3):227-33 [11535989.001]

[Cites] N Engl J Med. 2009 Jan 29;360(5):447-58 [19179314.001]

[Cites] Immunol Rev. 2009 Mar;228(1):41-57 [19290920.001]

[Cites] Immunol Rev. 2009 Mar;228(1):273-87 [19290934.001]

[Cites] Annu Rev Immunol. 2009;27:199-227 [19302039.001]

[Cites] Pediatr Transplant. 2009 Mar;13(2):244-50 [18822103.001]

[Cites] Immunol Res. 2009;43(1-3):223-42 [18979075.001]

[Cites] Clin Immunol. 2009 Apr;131(1):24-30 [19097825.001]

[Cites] Clin Immunol. 2009 May;131(2):179-88 [19217351.001]

[Cites] Blood. 2009 Apr 23;113(17):4114-24 [19168787.001]

[Cites] Pediatrics. 2009 May;123(5):e871-7 [19403480.001]

[Cites] Annu Rev Immunol. 2009;27:591-619 [19132916.001]

[Cites] Int J Mol Sci. 2009 Apr;10(4):1729-72 [19468337.001]

[Cites] Acta Paediatr. 2009 Jun;98(6):1062-4 [19243569.001]

[Cites] Immunol Res. 2009;44(1-3):4-17 [18592143.001]

[Cites] Immunol Res. 2009;44(1-3):61-70 [19066739.001]

[Cites] Br J Haematol. 2009 Apr;145(2):164-72 [19208095.001]

[Cites] Nat Rev Immunol. 2009 Jul;9(7):480-90 [19543225.001]

[Cites] Blood. 2009 Jul 2;114(1):105-8 [19414857.001]

[Cites] Eur J Med Genet. 2009 Nov-Dec;52(6):373-8 [19467349.001]

[Cites] Gene Ther. 2009 Nov;16(11):1285-91 [19776764.001]

[Cites] J Pediatr. 2009 Dec;155(6):834-840.e1 [19818451.001]

[Cites] Nat Rev Immunol. 2009 Dec;9(12):823-32 [19935802.001]

[Cites] Eur J Pediatr. 2010 Mar;169(3):311-4 [19657670.001]

[Cites] N Engl J Med. 2010 Jan 28;362(4):314-9 [20107217.001]

[Cites] J Allergy Clin Immunol. 2010 Jan;125(1):209-16 [20109747.001]

[Cites] Immunol Allergy Clin North Am. 2010 Feb;30(1):103-24 [20113889.001]

[Cites] Immunol Allergy Clin North Am. 2010 Feb;30(1):125-42 [20113890.001]

[Cites] Nat Rev Mol Cell Biol. 2010 Mar;11(3):171-81 [20125188.001]

[Cites] Clin Immunol. 2010 May;135(2):183-92 [20172764.001]

[Cites] Clin Immunol. 2010 May;135(2):169-82 [20189884.001]

[Cites] Clin Immunol. 2010 May;135(2):236-46 [20236866.001]

[Cites] Nat Immunol. 2010 Jun;11(6):457-60 [20485269.001]

[Cites] Immunol Allergy Clin North Am. 2010 May;30(2):173-8 [20493394.001]

[Cites] Immunol Allergy Clin North Am. 2010 May;30(2):221-36 [20493398.001]

[Cites] Public Health Rep. 2010 May-Jun;125 Suppl 2:88-95 [20518449.001]

[Cites] MMWR Morb Mortal Wkly Rep. 2010 Jun 11;59(22):687-8 [20535093.001]

[Cites] Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10097-102 [20479256.001]

[Cites] Immunology. 2010 Jun;130(2):166-71 [20557575.001]

[Cites] Am J Med Genet A. 2010 Aug;152A(8):ix [20662017.001]

[Cites] N Engl J Med. 2010 Jul 22;363(4):355-64 [20660403.001]

[Cites] Pediatrics. 2010 Aug;126(2):e465-9 [20603253.001]

[Cites] Blood. 2010 Aug 12;116(6):900-8 [20457870.001]

[Cites] J Allergy Clin Immunol. 2010 Sep;126(3):602-10.e1-11 [20673987.001]

[Cites] Nature. 2010 Sep 16;467(7313):318-22 [20844535.001]

[Cites] J Allergy Clin Immunol. 2010 Nov;126(5):1073-4 [20933257.001]

[Cites] Blood. 2007 Dec 15;110(13):4198-205 [17785587.001]

[Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]

[Cites] J Clin Immunol. 1999 Mar;19(2):87-97 [10226883.001]

[Cites] J Pediatr Surg. 2004 Nov;39(11):1607-15 [15547821.001]

(PMID = 21078154.001).

[ISSN] 1824-7288

[Journal-full-title] Italian journal of pediatrics

[ISO-abbreviation] Ital J Pediatr

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Other-IDs] NLM/ PMC2999594

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differential synergy of Notch and T cell receptor signaling determines alphabeta versus gammadelta lineage fate.

Thymic precursors expressing the pre-T cell receptor (TCR), the gammadeltaTCR, or the alphabetaTCR can all enter the CD4+ 8+ alphabeta lineage, albeit with different efficacy.

In particular, in alphabeta lineage commitment, the pre-TCR synergizes more efficiently with Notch signals than the other two TCRs, whereas gammadeltaTCR-expressing cells can survive and expand in the absence of Notch signals, even though Notch signaling enhances their proliferation.

These observations suggest a new model of alphabeta versus gammadelta lineage choice in which lineage fate is determined by the extent of synergy between TCR and Notch signaling and in which the evolutionarily recent advent of the cell-autonomously signaling pre-TCR increased the efficacy of alphabeta T cell generation.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2006 Jul 1;108(1):305-10 [16507772.001]

[Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4683-7 [8643464.001]

[Cites] Nature. 1995 Jun 29;375(6534):795-8 [7596413.001]

[Cites] Immunity. 2006 Jul;25(1):105-16 [16814577.001]

[Cites] Cell. 1996 Jul 26;86(2):243-51 [8706129.001]

[Cites] Nature. 2000 Aug 3;406(6795):524-7 [10952314.001]

[Cites] J Immunol. 2000 Nov 15;165(10):5566-72 [11067911.001]

[Cites] J Exp Med. 2000 Aug 21;192(4):537-48 [10952723.001]

[Cites] J Immunol. 2001 Mar 1;166(5):3184-93 [11207271.001]

[Cites] Immunity. 2001 Jul;15(1):71-82 [11485739.001]

[Cites] Nat Rev Immunol. 2001 Dec;1(3):193-9 [11905828.001]

[Cites] Nat Immunol. 2002 May;3(5):483-8 [11927911.001]

[Cites] Immunity. 2002 Dec;17(6):749-56 [12479821.001]

[Cites] EMBO J. 2003 Nov 3;22(21):5780-92 [14592976.001]

[Cites] J Exp Med. 2004 Mar 1;199(5):607-15 [14993248.001]

[Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]

[Cites] Immunity. 2004 May;20(5):611-22 [15142529.001]

[Cites] Adv Immunol. 2004;84:201-38 [15246254.001]

[Cites] Nature. 1985 Mar 7-13;314(6006):103-7 [2983227.001]

[Cites] Nature. 1985 May 16-22;315(6016):232-3 [3873615.001]

[Cites] Nature. 1987 Jun 25-Jul 1;327(6124):677-82 [2439914.001]

[Cites] Nature. 1988 Sep 15;335(6187):229-33 [2970593.001]

[Cites] J Exp Med. 1989 Mar 1;169(3):795-806 [2494291.001]

[Cites] Nature. 1989 Apr 13;338(6216):591-3 [2784545.001]

[Cites] Nature. 1989 Dec 21-28;342(6252):931-4 [2480528.001]

[Cites] EMBO J. 1991 Jan;10(1):93-100 [1703490.001]

[Cites] Cell. 1993 Oct 22;75(2):283-94 [8402912.001]

[Cites] Science. 1994 Nov 18;266(5188):1208-12 [7973703.001]

[Cites] Immunity. 1995 Jun;2(6):617-27 [7796295.001]

[Cites] Immunity. 1996 Oct;5(4):343-52 [8885867.001]

[Cites] J Immunol. 1997 Jan 1;158(1):65-75 [8977176.001]

[Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]

[Cites] J Exp Med. 1997 May 5;185(9):1541-7 [9151891.001]

[Cites] Immunity. 1997 Jul;7(1):83-95 [9252122.001]

[Cites] Immunity. 1998 Apr;8(4):427-38 [9586633.001]

[Cites] J Exp Med. 1998 Oct 19;188(8):1465-71 [9782123.001]

[Cites] Eur J Immunol. 1998 Nov;28(11):3456-67 [9842888.001]

[Cites] Immunity. 1998 Nov;9(5):649-55 [9846486.001]

[Cites] Immunol Rev. 1998 Oct;165:111-9 [9850856.001]

[Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]

[Cites] Blood. 2005 Feb 15;105(4):1440-7 [15486060.001]

[Cites] Immunity. 2005 May;22(5):583-93 [15894276.001]

[Cites] Immunity. 2005 May;22(5):595-606 [15894277.001]

[Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]

[Cites] Immunity. 2005 Oct;23(4):431-43 [16226508.001]

[Cites] Nat Immunol. 2006 Jan;7(1):67-75 [16327787.001]

[Cites] Immunity. 2006 Jan;24(1):53-64 [16413923.001]

(PMID = 16754723.001).

[ISSN] 0022-1007

[Journal-full-title] The Journal of experimental medicine

[ISO-abbreviation] J. Exp. Med.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / R01 AI045846; United States / NCI NIH HHS / CA / P01 CA10990; United States / NIAID NIH HHS / AI / R01 AI47281; United States / NIAID NIH HHS / AI / R01 AI047281; United States / NIAID NIH HHS / AI / R01 AI45846

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Notch; 128559-51-3 / RAG-1 protein

[Other-IDs] NLM/ PMC2118312

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Here, we studied T cell receptor (TCR) primary structure and function of 605 HLA-A*0201/NY-ESO-1(157-165)-specific CD8 T cell clones derived from five melanoma patients.

All remaining T cell clones belong to two additional sets expressing BV1 or BV13 TCRs, associated with alpha-chains with highly diverse VJ usage, CDR3 amino acid sequence, and length.

Yet, all T cell clonotypes recognize tumor antigen with similar functional avidity.

Two residues, Met-160 and Trp-161, located in the middle region of the NY-ESO-1(157-165) peptide, are critical for recognition by most of the T cell clonotypes.

[MeSH-major] Neoplasm Proteins / immunology. Peptide Fragments / immunology. Receptors, Antigen, T-Cell, alpha-beta / immunology

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. (L)-Methionine .

Hazardous Substances Data Bank. L-Threonine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]

[Cites] Protein Eng Des Sel. 2007 Aug;20(8):397-403 [17644531.001]

[Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):766s-772s [11300471.001]

[Cites] J Immunol. 2002 Apr 15;168(8):4231-40 [11937585.001]

[Cites] J Exp Med. 2002 Apr 15;195(8):991-1001 [11956290.001]

[Cites] Eur J Immunol. 2002 Nov;32(11):3181-90 [12555663.001]

[Cites] Annu Rev Immunol. 2003;21:659-84 [12615890.001]

[Cites] J Immunol. 2003 May 15;170(10):5103-9 [12734356.001]

[Cites] Nat Immunol. 2003 Jul;4(7):657-63 [12796775.001]

[Cites] Nat Rev Immunol. 2004 Feb;4(2):123-32 [15040585.001]

[Cites] Nature. 1974 Apr 19;248(5450):701-2 [4133807.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8987-90 [1833769.001]

[Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]

[Cites] J Exp Med. 1994 Dec 1;180(6):2335-40 [7964506.001]

[Cites] J Immunol. 1994 Dec 15;153(12):5586-92 [7527444.001]

[Cites] J Exp Med. 1998 May 18;187(10):1647-57 [9584143.001]

[Cites] J Exp Med. 2004 Dec 20;200(12):1547-57 [15596521.001]

[Cites] Immunity. 2005 Jan;22(1):117-29 [15664164.001]

[Cites] Nat Immunol. 2005 Mar;6(3):239-45 [15716973.001]

[Cites] J Exp Med. 2005 Apr 18;201(8):1243-55 [15837811.001]

[Cites] J Immunother. 2005 May-Jun;28(3):252-7 [15838382.001]

[Cites] Cancer Res. 2006 Feb 15;66(4):1912-6 [16488988.001]

[Cites] Annu Rev Immunol. 2006;24:419-66 [16551255.001]

[Cites] J Immunol. 2006 Nov 15;177(10):6804-14 [17082594.001]

[Cites] Eur J Immunol. 2007 Mar;37(3):838-48 [17323415.001]

[Cites] J Immunol. 2007 Aug 15;179(4):2368-79 [17675498.001]

[Cites] J Mol Biol. 2007 Sep 14;372(2):535-48 [17658550.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):2047-54 [11280765.001]

(PMID = 18809922.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / peptide NY-ESO-1 157-165; 2ZD004190S / Threonine; AE28F7PNPL / Methionine

[Other-IDs] NLM/ PMC2567484

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.

Nuclear factor kappa B (NF-kappaB) is one important pathway in T-cell proliferation and survival.

In a previously reported microarray study, we found NF-kappaB pathway genes differentially expressed between peripheral (PTCL) and lymphoblastic lymphomas.

This distinction was found among all T-cell lymphoma categories analyzed (PTCL unspecified, angioimmunoblastic, cutaneous and natural killer/T lymphomas) with the exception of anaplastic lymphomas (ALCL), which were characterized by reduced NF-kappaB expression in anaplastic cells.

[MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, T-Cell, Peripheral / genetics. NF-kappa B / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16270046.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / NF-kappa B

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias.

The t(9;22) BCR/ABL fusion is associated with over 90% of chronic myelogenous and 25% of acute lymphocytic leukemia.

Chromosome 11q23 translocations in acute myeloid and lymphoid leukemia cells demonstrate myeloid lymphoid leukemia (MLL) fusions with over 40 gene partners, like AF9 and AF4 on chromosomes 9 and 4, respectively.

Therapy-related leukemia is associated with the above gene rearrangements following the treatment with topoisomerase II (topo II) inhibitors.

In this report, using cell lines and primary cells, chromatin structural elements were analyzed in BCR, ABL and AF4 and, for comparison, in MLL2, which is a homolog to MLL, but not associated with chromosome translocations.

Although MLL2 was expressed in all cell lines tested, except for the presence of one DNAse I site in the promoter, no other structural elements were found in MLL2.

A NHR model presented demonstrates the importance of chromatin structure in chromosome translocations involved with leukemia.

[MeSH-major] Chromatin / chemistry. Chromosome Breakage. Chromosomes, Human / genetics. Leukemia / genetics. Leukemia / metabolism. Translocation, Genetic

[MeSH-minor] Acute Disease. Cell Line, Tumor. Cells, Cultured. Chronic Disease. Humans. K562 Cells. Proto-Oncogene Proteins c-bcr / chemistry. Proto-Oncogene Proteins c-bcr / genetics. Recombination, Genetic

MedlinePlus Health Information. consumer health - Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochemistry. 1997 May 20;36(20):5934-9 [9166762.001]

[Cites] Cell. 1985 May;41(1):127-32 [2986841.001]

[Cites] Gene. 2002 May 29;291(1-2):251-7 [12095698.001]

[Cites] EMBO J. 1990 Apr;9(4):1319-27 [2323342.001]

[Cites] Science. 1994 Jan 28;263(5146):515-8 [8290959.001]

[Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):923-6 [10959840.001]

[Cites] Leukemia. 1996 Feb;10(2):372-7 [8637251.001]

[Cites] J Cell Biochem. 2001;82(2):299-309 [11527155.001]

[Cites] Genomics. 1995 May 1;27(1):67-82 [7665185.001]

[Cites] Annu Rev Biochem. 1989;58:351-75 [2549853.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9 [8016145.001]

[Cites] Oncogene. 1989 May;4(5):559-67 [2657572.001]

[Cites] Oncogene. 1990 Nov;5(11):1669-73 [2267134.001]

[Cites] Oncogene. 2001 May 24;20(23):2900-7 [11420702.001]

[Cites] J Cell Biol. 2001 Dec 10;155(6):899-910 [11739403.001]

[Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4790-5 [10758153.001]

[Cites] EMBO J. 2002 Oct 1;21(19):5269-80 [12356743.001]

[Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):144-54 [11550282.001]

[Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):393-401 [12619163.001]

[Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2076-80 [2832845.001]

[Cites] Nucleic Acids Res. 1997 Feb 1;25(3):511-7 [9016589.001]

[Cites] Cancer Res. 1999 Jul 15;59(14 ):3357-62 [10416593.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98 (17 ):9802-7 [11493704.001]

[Cites] Oncogene. 1998 Dec 3;17(22):2921-31 [9879998.001]

[Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4583-90 [15331666.001]

[Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5533-56 [2838820.001]

[Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5497-501 [2546156.001]

[Cites] Cell. 1995 Dec 29;83(7):1137-48 [8548801.001]

[Cites] J Cell Biochem Suppl. 2000;Suppl 35:3-22 [11389527.001]

[Cites] Hum Mol Genet. 1998 May;7(5):767-76 [9536079.001]

[Cites] Hum Mol Genet. 2000 Jul 1;9(11):1671-9 [10861294.001]

[Cites] Mol Cell Biol. 1991 Oct;11(10):4973-84 [1656219.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14535-40 [10588740.001]

[Cites] Cell Mol Life Sci. 2002 Feb;59(2):373-85 [11915950.001]

[Cites] Mol Cell Biol. 1997 Jul;17(7):4070-9 [9199342.001]

[Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):681-95 [7980433.001]

[Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]

[Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10 ):4631-5 [8506309.001]

[Cites] Hum Mol Genet. 2002 Jun 1;11(12):1391-7 [12023981.001]

[Cites] J Biol Chem. 2002 Jun 14;277(24):21458-67 [11940566.001]

[Cites] Hum Mutat. 2003 Sep;22(3):229-44 [12938088.001]

[Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]

[Cites] Oncogene. 1998 Dec 10;17 (23 ):3035-44 [9881706.001]

[Cites] Genomics. 1999 Jul 15;59(2):187-92 [10409430.001]

[Cites] Leuk Res. 2002 Aug;26(8):713-20 [12191565.001]

[Cites] Br J Haematol. 1999 Apr;105(1):256-64 [10233389.001]

[Cites] Blood. 2000 Feb 1;95(3):738-43 [10648381.001]

[Cites] Oncogene. 1999 Dec 23;18(56):7975-84 [10637508.001]

[Cites] Cancer Res. 1995 Jan 1;55(1):34-8 [7805037.001]

[Cites] Cancer Res. 1996 Apr 15;56(8):1855-62 [8620504.001]

[Cites] Blood. 1996 Mar 1;87(5):1912-22 [8634439.001]

[Cites] Nature. 2001 Sep 27;413(6854):435-8 [11574892.001]

[Cites] Cancer Lett. 2003 Apr 10;193(1):1-9 [12691817.001]

[Cites] Leukemia. 1997 Sep;11(9):1571-4 [9305614.001]

[Cites] Chromosoma. 1996 Aug;105(2):122-33 [8753702.001]

[Cites] Leukemia. 1999 Dec;13(12):2107-13 [10602437.001]

[Cites] Cancer Res. 1993 Oct 1;53(19):4489-92 [8402620.001]

[Cites] Mol Cell Biol. 1999 Apr;19(4):2986-97 [10082566.001]

[Cites] Hum Genet. 2003 Jul;113(1):80-91 [12665971.001]

[Cites] Blood. 1998 Nov 15;92(10):3793-803 [9808573.001]

[Cites] Genomics. 1998 Jan 15;47(2):217-29 [9479494.001]

[Cites] Blood. 2001 Dec 15;98(13):3778-83 [11739186.001]

[Cites] Genes Dev. 2001 Dec 15;15(24):3237-42 [11751629.001]

[Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):92-6 [12203795.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]

[Cites] Blood. 1990 Aug 1;76(3):597-601 [2198962.001]

[Cites] Genetics. 2002 Apr;160(4):1363-73 [11973293.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9882-7 [12114534.001]

[Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]

[Cites] FASEB J. 2004 Jan;18(1):173-5 [14630694.001]

[Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):362-78 [11921271.001]

[Cites] Mol Pharmacol. 1998 Jul;54(1):78-85 [9658192.001]

[Cites] Cancer Res. 2004 Apr 15;64(8):2656-62 [15087374.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3070-5 [11867721.001]

[Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]

[Cites] Chromosoma. 1991 Feb;100(2):97-102 [1849068.001]

[Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]

[Cites] Leukemia. 1995 Aug;9(8):1305-12 [7643617.001]

(PMID = 16572268.001).

[ISSN] 0340-6717

[Journal-full-title] Human genetics

[ISO-abbreviation] Hum. Genet.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies

[Publication-country] Germany

[Chemical-registry-number] 0 / Chromatin; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia.

BACKGROUND AND OBJECTIVES: ZAP-70 expression is a recognized prognostic marker in chronic lymphocytic leukemia (CLL).

DESIGN AND METHODS: Patients with CLL (n=87), acute lymphoblastic leukemia (n=13), mantle cell leukemia (n=13) and splenic marginal zone lymphoma (n=14) of known immunoglobulin gene mutation (IgVH) status were studied.

[MeSH-major] DNA Methylation. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics

[MeSH-minor] 5' Untranslated Regions / genetics. Conserved Sequence. Dinucleoside Phosphates / genetics. Humans. Introns. Leukemia / genetics. Reference Values. Restriction Mapping

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Haematologica. 2005 Aug;90(8):1012 [16079094.001]

(PMID = 16079107.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Dinucleoside Phosphates; 2382-65-2 / cytidylyl-3'-5'-guanosine; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Treatment results of acute leukemia in elderly patients: analysis of 61 consecutive patients in a single institution].

In order to investigate the clinical characteristics and management of elderly patients with acute leukemia, we retrospectively analyzed treatment results for 61 acute leukemia patients aged 65 years or more (median age 72) admitted to our department between October 1995 and September 2006.

There were 6 elderly patients with ALL (acute lymphocytic leukemia) and 55 patients with AML (acute myelogenous leukemia).

The intensive chemotherapy group and the de novo leukemia group showed a significantly higher CR rate and longer survival.

Intensive chemotherapy was effective for 65-74-year-old patients with de novo AML.

In future, we consider that the prognosis for elderly patients with acute leukemia will improve, if made-to-order treatment is given, depending on evidence-based stratification of patients with organs having low reserve capacity.

[MeSH-major] Leukemia, Lymphoid / drug therapy. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Acute Disease. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Male. Retrospective Studies. Survival Rate

MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18281758.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-cell receptor gamma and delta junctional gene rearrangements as diagnostic and prognostic biomarker for T-cell acute lymphoblastic leukemia.

[MeSH-major] Biomarkers, Tumor. Gene Rearrangement. Leukemia, T-Cell / diagnosis. Leukemia, T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, gamma-delta / metabolism

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16886283.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Letter

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, T-Cell, gamma-delta

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Heritable T-cell malignancy models established in a zebrafish phenotypic screen.

T-cell neoplasias are common in pediatric oncology, and include acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).

These cancers have worse prognoses than their B-cell counterparts, and their treatments carry significant morbidity.

Although many pediatric malignancies have characteristic translocations, most T-lymphocyte-derived diseases lack cytogenetic hallmarks.

Although dysregulation of the NOTCH1 pathway occurs in a substantial fraction of cases, many other genetic lesions of T-cell malignancy have not yet been determined.

Using transgenic fish with T-lymphocyte-specific expression of enhanced green fluorescent protein (EGFP), we performed chemical mutagenesis, screened animals for GFP(+) tumors, and identified multiple lines with a heritable predisposition to T-cell malignancy.

T-cell receptor analyses confirmed their clonality.

Malignancies were transplantable and contained leukemia-initiating cells, like their human correlates.

In summary, we have identified multiple zebrafish mutants that recapitulate human T-cell neoplasia and show heritable transmission.

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

ZFIN. ZFIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]

[Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]

[Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):91-113; discussion 200-2 [12196211.001]

[Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]

[Cites] Curr Opin Hematol. 2003 Jul;10(4):290-6 [12799535.001]

[Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]

[Cites] Nat Immunol. 2003 Dec;4(12):1238-46 [14608381.001]

[Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):246-61 [14757442.001]

[Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]

[Cites] Immunity. 2004 Apr;20(4):367-79 [15084267.001]

[Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7369-74 [15123839.001]

[Cites] Blood. 2004 Sep 1;104(5):1298-305 [15142873.001]

[Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]

[Cites] Ann Intern Med. 1975 Oct;83(4):534-52 [126656.001]

[Cites] Scand J Haematol. 1975 Sep;15(2):117-31 [1188315.001]

[Cites] Nature. 1981 May 28;291(5813):293-6 [7248006.001]

[Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]

[Cites] Genetics. 1994 Apr;136(4):1401-20 [8013916.001]

[Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]

[Cites] Development. 1996 Dec;123:1-36 [9007226.001]

[Cites] Leukemia. 1997 Aug;11(8):1347-59 [9264391.001]

[Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]

[Cites] Curr Opin Hematol. 1998 Jul;5(4):292-301 [9747636.001]

[Cites] Blood. 2005 Apr 15;105(8):3278-85 [15618471.001]

[Cites] Ultrastruct Pathol. 2005 May-Aug;29(3-4):175-202 [16036874.001]

[Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]

[Cites] Best Pract Res Clin Haematol. 2006;19(2):269-79 [16516124.001]

[Cites] Leukemia. 2006 Sep;20(9):1496-510 [16826225.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15166-71 [17015828.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]

[Cites] BMC Genomics. 2007;8:11 [17212827.001]

[Cites] Leukemia. 2007 Mar;21(3):462-71 [17252014.001]

[Cites] J Med Genet. 2007 Jul;44(7):e83 [17601929.001]

[Cites] Development. 2007 Dec;134(23):4147-56 [17959717.001]

[Cites] WormBook. 2006;:1-6 [18050456.001]

[Cites] Dev Comp Immunol. 2008;32(7):745-57 [18222541.001]

[Cites] Oncogene. 2008 Jul 10;27(30):4242-8 [18345029.001]

[Cites] Dev Dyn. 2008 Sep;237(9):2575-84 [18729230.001]

[Cites] Br J Haematol. 2008 Nov;143(3):378-82 [18729850.001]

[Cites] Semin Hematol. 2009 Jan;46(1):33-8 [19100366.001]

[Cites] Dev Biol. 1999 Dec 1;216(1):1-15 [10588859.001]

[Cites] Science. 2000 Mar 17;287(5460):2032-6 [10720333.001]

[Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]

[Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]

[Cites] Curr Opin Hematol. 2001 Jul;8(4):189-91 [11561153.001]

(PMID = 19516274.001).

[ISSN] 1476-5551

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] ENG

[Grant] United States / NICHD NIH HHS / HD / K08 HD053350-03; United States / NCI NIH HHS / CA / P30-CA042014; United States / NICHD NIH HHS / HD / K08-HD53350; United States / NICHD NIH HHS / HD / R21 HD060310; United States / NICHD NIH HHS / HD / R21 HD060310-01; United States / NIDDK NIH HHS / DK / T32-DK007115; United States / NIDDK NIH HHS / DK / T32 DK007115; United States / NICHD NIH HHS / HD / K08 HD053350; United States / NIAID NIH HHS / AI / R21-AI079784; United States / NICHD NIH HHS / HD / K12 HD001410; United States / NICHD NIH HHS / HD / K12-HD001410; United States / NICHD NIH HHS / HD / K08 HD053350-02; United States / NCI NIH HHS / CA / P30 CA042014

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins

[Other-IDs] NLM/ NIHMS112911; NLM/ PMC2761994

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.

In the T-cell lineage, calcineurin activation is important for pre-T-cell receptor (TCR) signaling, TCR-mediated positive selection of thymocytes into mature T cells, and many aspects of the immune response.

We observed sustained calcineurin activation in human B- and T-cell lymphomas and in all mouse models of lymphoid malignancies analyzed.

In intracellular NOTCH1 (ICN1)- and TEL-JAK2-induced T-cell lymphoblastic leukemia, two mouse models relevant to human malignancies, in vivo inhibition of calcineurin activity by CsA or FK506 induced apoptosis of leukemic cells and rapid tumor clearance, and substantially prolonged mouse survival.

In contrast, ectopic expression of a constitutively activated mutant of calcineurin favored leukemia progression.

Moreover, CsA treatment induced apoptosis in human lymphoma and leukemia cell lines.

[MeSH-major] Antineoplastic Agents / pharmacology. Calcineurin / metabolism. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / enzymology

[MeSH-minor] Animals. Calcineurin Inhibitors. Cell Line, Tumor. Cyclosporine / pharmacology. Disease Models, Animal. Enzyme Activation / drug effects. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Oncogene Proteins, Fusion / deficiency. Oncogene Proteins, Fusion / genetics. Receptor, Notch1 / physiology. Tacrolimus / pharmacology

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYCLOSPORIN A .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Nat Med. 2007 Jun;13(6):669-71 [17554330.001]

(PMID = 17515895.001).

[ISSN] 1078-8956

[Journal-full-title] Nature medicine

[ISO-abbreviation] Nat. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calcineurin Inhibitors; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Receptor, Notch1; 0 / TEL-JAK2 fusion protein, mouse; 83HN0GTJ6D / Cyclosporine; EC 3.1.3.16 / Calcineurin; WM0HAQ4WNM / Tacrolimus

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format.

The signal transducers and activators of transcription (STAT) proteins are a small family of signaling proteins that are crucial for cytokine and growth factor receptor-mediated signaling in various blood cell types.

Despite their central role in immune and hematopoietic cellular regulation, there are relatively few options for monitoring receptor-mediated JAK/STAT signaling events in a cell-based format, without the need for cellular transfections or labor intensive methodology.

With three different cell lines (human acute monocytic leukemia THP-1 cells, human erythroleukemic TF-1 cells, and human T lymphocytic Jurkat cells), we have optimized a rapid and homogeneous methodology for monitoring endogenous, receptor-mediated signaling via STAT 1, STAT 3, or STAT 5 phosphorylation, in response to several agonists.

[MeSH-minor] Biochemistry / methods. Blotting, Western. Cell Line, Tumor. Humans. Jurkat Cells. Phosphorylation. STAT1 Transcription Factor / metabolism. STAT3 Transcription Factor / metabolism. STAT5 Transcription Factor / metabolism

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 20382104.001).

[ISSN] 1096-0309

[Journal-full-title] Analytical biochemistry

[ISO-abbreviation] Anal. Biochem.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Cytokine; 0 / STAT Transcription Factors; 0 / STAT1 Transcription Factor; 0 / STAT3 Transcription Factor; 0 / STAT5 Transcription Factor

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia.

PURPOSE: Polyunsaturated fatty acids (PUFA) and the sulfur-substituted fatty acid tetradecylthioacetic acid (TTA) inhibit proliferation and induce apoptosis in lymphoma and leukemic cell lines, but it is unknown if they can modify leukemogenesis in the intact organism.

EXPERIMENTAL DESIGN: We now examined the effects of PUFA and TTA in rats transplanted with either acute promyelocytic leukemia or acute T-cell leukemia.

RESULTS: Whereas TTA prolonged survival (P < 0.05) in both types of rat leukemia, n-3 PUFA had no significant effect compared with controls.

CONCLUSIONS: Dietary intake of TTA, but not of n-3 PUFA, in rats with acute leukemia, prolonged their survival.

TTA intake was also associated with reduced leukemic cell burden as well as diminished extramedullar dissemination.

TTA represents a modified fatty acid that exerts unique effects on malignant hematopoietic cells, and the present study indicates that TTA may have a therapeutic potential in patients with acute leukemias.

[MeSH-major] Fatty Acids, Unsaturated / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Sulfides / administration & dosage

[MeSH-minor] Animals. Apoptosis / drug effects. Diet. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Enzyme Activation / drug effects. Humans. Leukemic Infiltration / diagnosis. Matrix Metalloproteinases / drug effects. Neoplasm Metastasis. Rats. Structure-Activity Relationship. Survival Rate. Transplantation, Heterologous. Xenograft Model Antitumor Assays

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16740779.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Fatty Acids, Unsaturated; 0 / Sulfides; 2921-20-2 / 1-(carboxymethylthio)tetradecane; EC 3.4.24.- / Matrix Metalloproteinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

On three separate nights, they provided pre-activity, post-activity, and next-morning saliva samples and completed brief questionnaires at the last two timepoints.

Women's T was higher pre-intercourse than pre-control activity.

Women's T was also higher post-intercourse than post-control activity, though the percent change in T from pre- to post-activity was highest for cuddling, then intercourse, then exercise.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. TESTOSTERONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17320881.001).

[ISSN] 0018-506X

[Journal-full-title] Hormones and behavior

[ISO-abbreviation] Horm Behav

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 3XMK78S47O / Testosterone

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Thus, expression of these critical regulators is dependent on continued expression of upstream regulators, which may include cell-extrinsic signals.

[MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Cell Line. DNA / metabolism. Embryo, Nonmammalian / cytology. Embryo, Nonmammalian / embryology. Embryo, Nonmammalian / metabolism. Endothelial Cells / cytology. Endothelial Cells / metabolism. Erythroid Cells / cytology. Erythroid Cells / metabolism. Gene Expression Regulation, Developmental. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / metabolism. LIM Domain Proteins. Mice. Myeloid Cells / cytology. Myeloid Cells / metabolism. Phenotype. Protein Binding. Transcription Factors

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

ZFIN. ZFIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17090656.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Grant] United States / NIGMS NIH HHS / GM / GM63904; United Kingdom / Medical Research Council / / MC/ U137981013; United States / NCI NIH HHS / CA / P01CA65493; United States / NIGMS NIH HHS / GM / R01 GM063904-01; United States / NIGMS NIH HHS / GM / R01 GM063904

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / Lmo2 protein, mouse; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / Zebrafish Proteins; 0 / lmo2 protein, zebrafish; 0 / tal1 protein, zebrafish; 9007-49-2 / DNA

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Nelarabine is indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma whose disease has not responded to, or has relapsed after treatment with, at least two chemotherapy regimens.

[MeSH-major] Arabinonucleosides / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

COS Scholar Universe. author profiles.

SciCrunch. DrugBank: Data: Chemical .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16922610.001).

[ISSN] 1479-6694

[Journal-full-title] Future oncology (London, England)

[ISO-abbreviation] Future Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine

[Number-of-references] 22

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Analysis of null mutants showed that Gli3 is involved at the transitions from DN1 to CD44+ CD25+ DN (DN2) cell and from DN to CD4+ CD8+ double-positive (DP) cell.

Gli3 is required for differentiation from DN to DP thymocyte, after pre-T-cell receptor (TCR) signaling but is not necessary for pre-TCR-induced proliferation or survival.

The effect of Gli3 was dose dependent, suggesting its direct involvement in the transcriptional regulation of genes controlling T-cell differentiation during fetal development.

[MeSH-major] Antigens, CD / analysis. Cell Differentiation. DNA-Binding Proteins / physiology. Nerve Tissue Proteins / physiology. T-Lymphocytes / cytology. Thymus Gland / cytology. Transcription Factors / physiology

[MeSH-minor] Animals. Antigens, CD4. Antigens, CD8. Cell Lineage. Embryo, Mammalian / cytology. Embryo, Mammalian / immunology. Gene Expression Regulation, Developmental. Kruppel-Like Transcription Factors. Mice. Mice, Inbred C57BL. Mice, Mutant Strains

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Development. 2000 Apr;127(8):1593-605 [10725236.001]

[Cites] Immunity. 2000 Apr;12(4):441-50 [10795742.001]

[Cites] J Embryol Exp Morphol. 1967 Jun;17(3):543-81 [6049666.001]

[Cites] Immunol Rev. 1986 Jun;91:129-57 [3525392.001]

[Cites] J Immunol. 1987 Feb 15;138(4):1026-30 [2879866.001]

[Cites] Nature. 1991 Aug 8;352(6335):539-40 [1650914.001]

[Cites] Cell. 2000 Aug 18;102(4):521-31 [10966113.001]

[Cites] Development. 2000 Oct;127(19):4293-301 [10976059.001]

[Cites] Cell. 1992 Mar 6;68(5):869-77 [1547488.001]

[Cites] EMBO J. 1992 Dec;11(13):4877-86 [1334460.001]

[Cites] Development. 1992 Nov;116(3):799-804 [1289066.001]

[Cites] Nat Genet. 1993 Mar;3(3):241-6 [8387379.001]

[Cites] Cell. 1993 Oct 22;75(2):283-94 [8402912.001]

[Cites] Immunity. 2000 Aug;13(2):187-97 [10981962.001]

[Cites] Semin Immunol. 2000 Oct;12(5):421-8 [11085174.001]

[Cites] Eur J Immunol. 2001 Jan;31(1):285-93 [11265645.001]

[Cites] J Immunol. 2001 Jun 1;166(11):6593-601 [11359812.001]

[Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]

[Cites] Eur J Immunol. 2001 Nov;31(11):3308-17 [11745348.001]

[Cites] Mamm Genome. 2002 Jan;13(1):58-61 [11773971.001]

[Cites] Genes Dev. 2002 Feb 15;16(4):421-6 [11850405.001]

[Cites] Curr Opin Immunol. 2002 Apr;14(2):200-6 [11869893.001]

[Cites] Differentiation. 2002 May;70(2-3):69-76 [12076333.001]

[Cites] J Exp Med. 2002 Jul 15;196(2):163-71 [12119341.001]

[Cites] Immunity. 2002 Jun;16(6):869-79 [12121668.001]

[Cites] Nature. 2002 Aug 29;418(6901):979-83 [12198547.001]

[Cites] Semin Immunol. 2002 Oct;14(5):311-23 [12220932.001]

[Cites] Development. 2002 Oct;129(20):4753-61 [12361967.001]

[Cites] Science. 2002 Oct 25;298(5594):827-30 [12215652.001]

[Cites] Nat Rev Immunol. 2002 Nov;2(11):888-97 [12415312.001]

[Cites] J Immunol. 2002 Nov 15;169(10):5496-504 [12421925.001]

[Cites] Genes Dev. 2002 Nov 15;16(22):2843-8 [12435627.001]

[Cites] Semin Immunol. 2002 Dec;14(6):431-40 [12457616.001]

[Cites] Curr Opin Immunol. 2003 Apr;15(2):204-8 [12633671.001]

[Cites] Dev Biol. 2003 Aug 15;260(2):484-95 [12921747.001]

[Cites] Dev Cell. 2004 Jan;6(1):103-15 [14723851.001]

[Cites] J Immunol. 2004 Feb 15;172(4):2296-306 [14764698.001]

[Cites] Curr Opin Genet Dev. 2004 Feb;14(1):65-70 [15108807.001]

[Cites] Dev Dyn. 2004 Sep;231(1):148-60 [15305295.001]

[Cites] J Immunol. 2004 Oct 15;173(8):5046-53 [15470048.001]

[Cites] J Immunol. 1992 Mar 15;148(6):1604-12 [1347301.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11401-5 [8248261.001]

[Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]

[Cites] Blood. 1995 Sep 1;86(5):1850-60 [7655014.001]

[Cites] Eur J Immunol. 1996 Apr;26(4):804-10 [8625971.001]

[Cites] Annu Rev Immunol. 1996;14:29-47 [8717506.001]

[Cites] Dev Biol. 1996 Nov 25;180(1):273-83 [8948590.001]

[Cites] Development. 1997 Jan;124(1):113-23 [9006072.001]

[Cites] J Exp Med. 1996 Sep 1;184(3):903-11 [9064350.001]

[Cites] Nat Genet. 1997 Mar;15(3):266-8 [9054938.001]

[Cites] Annu Rev Immunol. 1997;15:155-76 [9143685.001]

[Cites] Immunity. 1997 Nov;7(5):601-7 [9390684.001]

[Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]

[Cites] Curr Opin Immunol. 1997 Apr;9(2):222-7 [9099800.001]

[Cites] Development. 1998 Jun;125(12):2315-25 [9584130.001]

[Cites] Development. 1998 Jul;125(14):2533-43 [9636069.001]

[Cites] Eur J Immunol. 1998 Jun;28(6):1859-66 [9645367.001]

[Cites] Development. 1998 Aug;125(15):2759-70 [9655799.001]

[Cites] J Biol Chem. 1999 Mar 19;274(12):8143-52 [10075717.001]

[Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]

[Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]

[Cites] Development. 1999 Sep;126(17):3915-24 [10433919.001]

[Cites] Trends Genet. 1999 Oct;15(10):418-25 [10498938.001]

[Cites] Oncogene. 1999 Dec 20;18(55):7852-9 [10630638.001]

[Cites] Cell. 2000 Feb 18;100(4):423-34 [10693759.001]

[Cites] Curr Opin Immunol. 2000 Apr;12(2):144-50 [10712944.001]

(PMID = 15855276.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Grant] United Kingdom / Wellcome Trust / / 061000; United Kingdom / Wellcome Trust / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / DNA-Binding Proteins; 0 / Gli3 protein, mouse; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Transcription Factors

[Other-IDs] NLM/ PMC1274277; NLM/ UKMS5313

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.

Mutually exclusive oncogenic rearrangements may delineate specific T-cell acute lymphoblastic leukaemia (T-ALL) subgroups, and so far at least 4 molecular-cytogenetic subgroups have been identified, i.e. the TAL/LMO, the TLX1/HOX11, the TLX3/HOX11L2 and the HOXA subgroups.

A fifth group with an immature immunophenotype that can be predicted by an early T-cell precursor signature has also been identified, and has been associated with poor outcome.

The association of these subgroups with the expression of specific immunophenotypic markers reflecting arrest at specific T-cell developmental stages will be reviewed.

[MeSH-major] Gene Rearrangement. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Signal Transduction

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.

(PMID = 21112032.001).

[ISSN] 1532-1924

[Journal-full-title] Best practice & research. Clinical haematology

[ISO-abbreviation] Best Pract Res Clin Haematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NOTCH1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 135471-20-4 / TAL1 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The treatment of adolescents and young adults with acute lymphoblastic leukemia.

Intensive chemotherapy regimens for children with acute lymphoblastic leukemia (ALL) have greatly improved, and the majority of children with precursor B-cell ALL are able to achieve a complete remission (CR), with an induction rate approaching 98% and a 5-year estimated event-free survival rate (EFS) of approximately 80%.

In addition, new insights into the molecular pathogenesis of T cell ALL have led to new therapeutic strategies.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16304369.001).

[ISSN] 1520-4383

[Journal-full-title] Hematology. American Society of Hematology. Education Program

[ISO-abbreviation] Hematology Am Soc Hematol Educ Program

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this study, we covalently link the antitumor agent doxorubicin (Dox) to the DNA aptamer sgc8c, which was selected by the cell-SELEX method.

In doing so, we expected that this sgc8c-Dox conjugate would specifically kill the target CCRF-CEM (T-cell acute lymphoblastic leukemia, T-cell ALL) cells, but with minimal toxicity towards nontarget cells.

Cell viability tests demonstrate that the sgc8c-Dox conjugates not only possess potency similar to unconjugated Dox, but also have the required molecular specificity that is lacking in most current targeted drug delivery strategies.

Furthermore, we found that nonspecific uptake of membrane-permeable Dox to nontarget cell lines could also be inhibited by linking the drug with the aptamer; thus, the conjugates are selective for cells that express higher amounts of target proteins.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2001 May 11;276(19):16464-8 [11279054.001]

[Cites] Bioconjug Chem. 1993 Nov-Dec;4(6):521-7 [7508268.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15416-21 [14676325.001]

[Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(8):2258-62 [6300903.001]

[Cites] Cancer Chemother Pharmacol. 1986;18(3):185-97 [2948729.001]

[Cites] Science. 1990 Aug 3;249(4968):505-10 [2200121.001]

[Cites] Nature. 1990 Aug 30;346(6287):818-22 [1697402.001]

[Cites] Bioorg Med Chem. 1995 Oct;3(10):1305-12 [8564396.001]

[Cites] Anal Chem. 2005 Apr 15;77(8):2281-7 [15828758.001]

[Cites] Expert Opin Drug Deliv. 2006 May;3(3):311-24 [16640493.001]

[Cites] Cancer Res. 2006 Jun 15;66(12):5989-92 [16778167.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11838-43 [16873550.001]

[Cites] Nat Biotechnol. 2006 Aug;24(8):1005-15 [16823371.001]

[Cites] Angew Chem Int Ed Engl. 2006 Dec 11;45(48):8149-52 [17099918.001]

[Cites] Chembiochem. 2007 Apr 16;8(6):603-6 [17373017.001]

[Cites] Clin Chem. 2007 Jun;53(6):1153-5 [17463173.001]

[Cites] Acc Chem Res. 2008 Jan;41(1):98-107 [17705444.001]

[Cites] Anal Chem. 2008 Feb 1;80(3):721-8 [18177018.001]

[Cites] Chemistry. 2008;14(6):1769-75 [18092308.001]

[Cites] Bioconjug Chem. 2008 Feb;19(2):525-31 [18163537.001]

[Cites] J Proteome Res. 2008 May;7(5):2133-9 [18363322.001]

[Cites] Cancer J. 2008 May-Jun;14(3):154-69 [18536555.001]

[Cites] ChemMedChem. 2008 Jun;3(6):991-1001 [18338423.001]

[Cites] Cancer Cell. 2003 Mar;3(3):207-12 [12676579.001]

(PMID = 19253922.001).

[ISSN] 1439-7633

[Journal-full-title] Chembiochem : a European journal of chemical biology

[ISO-abbreviation] Chembiochem

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / R01 GM079359; United States / NIGMS NIH HHS / GM / R01 GM079359-01; None / None / / R01 GM079359-01; United States / NIGMS NIH HHS / GM / R01 GM079359-02; United States / NIGMS NIH HHS / GM / R01 GM079359-03; None / None / / R01 GM079359-02; None / None / / R01 GM079359-01S1; United States / NIGMS NIH HHS / GM / R01 GM079359-01S1

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aptamers, Nucleotide; 0 / Drug Carriers; 0 / Immunoconjugates; 80168379AG / Doxorubicin

[Other-IDs] NLM/ NIHMS149610; NLM/ PMC2992821

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In order to fully understand T cell-mediated immunity, the mechanisms that regulate clonal expansion and cytokine production by CD4(+) antigen-specific effector T cells in response to a wide range of antigenic stimulation needs clarification.

For this purpose, panels of antigen-specific CD4(+) T cell clones with different thresholds for antigen-induced proliferation were generated by repeated stimulation with high- or low-dose antigen.

There was no significant difference in antigen-dependent cytokine production by TG40 cells transfected with TCR obtained from either high- or low-dose-responding T cell clones, suggesting that the affinity of TCRs for their ligands is not primary determinant of T cell antigen reactivity.

The proliferative responses of all T cell clones to both peptide stimulation and to TCRbeta crosslinking revealed parallel dose-response curves.

Finally, the antigen responses of high- and low-peptide-responding T cell clones reveal that clonal expansion and cytokine production of effector T cells occur independently of antigen concentration.

[MeSH-minor] Animals. Cell Adhesion Molecules / metabolism. Clone Cells. Flow Cytometry. Mice. Mice, Inbred BALB C. Ovalbumin / immunology. Peptide Fragments / immunology. Receptors, Antigen, T-Cell / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19338745.001).

[ISSN] 1090-2104

[Journal-full-title] Biochemical and biophysical research communications

[ISO-abbreviation] Biochem. Biophys. Res. Commun.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / OVA 323-339; 0 / Peptide Fragments; 0 / Receptors, Antigen, T-Cell; 9006-59-1 / Ovalbumin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.

Control of apoptosis via death ligands plays a basic role for lymphocyte homeostasis and lymphoma development.

In this study, cutaneous T-cell lymphoma (CTCL) cell lines revealed pronounced resistance to death ligands as compared to cell lines of T-cell acute lymphoblastic leukemia (T-ALL).

The proapoptotic activity of tumor necrosis factor (TNF)-alpha was blocked, sensitivity to TNF-related apoptosis-inducing ligand was significantly reduced, and 1/4 CTCL cell lines was resistant to CD95 activation.

No indication for a responsibility of typical downstream regulators of apoptosis was obtained, but loss of CD95 was found in 1/4, loss of TNF-R1 in 3/4, loss of caspase-10 in 2/4, loss of Bid in 1/4, and overexpression of cellular flice inhibitory protein was found in 4/4 CTCL cell lines.

[MeSH-major] Apoptosis / physiology. Lymphoma, T-Cell, Cutaneous / pathology. Receptors, Death Domain / antagonists & inhibitors. Signal Transduction / physiology. Skin Neoplasms / pathology

[MeSH-minor] Aged. Antigens, CD95 / physiology. BH3 Interacting Domain Death Agonist Protein / physiology. CASP8 and FADD-Like Apoptosis Regulating Protein / physiology. Caspase 10 / physiology. Cell Line, Tumor. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / physiopathology. Male. Middle Aged. TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / physiology. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / physiology

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17495957.001).

[ISSN] 1523-1747

[Journal-full-title] The Journal of investigative dermatology

[ISO-abbreviation] J. Invest. Dermatol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD95; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Receptors, Death Domain; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / Caspase 10

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Genetic studies have demonstrated that the Bcl-2 family member Mcl-1 is an important anti-apoptotic protein in the development of multiple cell types including T lymphocytes.

In this study, we examined the expression pattern of Mcl-1 in different populations of T cells at the single-cell level and found that Mcl-1 protein is constitutively expressed in all T cell populations and up-regulated upon TCR stimulation.

We then investigated the role of Mcl-1 in the survival of these different populations by conditionally deleting Mcl-1 at various T cell stages.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol. 1993 Jul 1;151(1):83-91 [8326141.001]

[Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20 [7682708.001]

[Cites] Science. 1993 Sep 17;261(5128):1584-8 [8372353.001]

[Cites] Cell. 1993 Oct 22;75(2):229-40 [8402909.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10685-9 [7938012.001]

[Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]

[Cites] Science. 1995 Mar 10;267(5203):1506-10 [7878471.001]

[Cites] J Exp Med. 1995 Apr 1;181(4):1519-26 [7699333.001]

[Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4763-7 [7761398.001]

[Cites] Immunity. 1995 Jul;3(1):87-98 [7621080.001]

[Cites] EMBO J. 1995 Oct 2;14(19):4641-53 [7588594.001]

[Cites] J Exp Med. 1995 Dec 1;182(6):1973-83 [7500043.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12070-4 [8618846.001]

[Cites] Science. 1996 Jun 28;272(5270):1947-50 [8658169.001]

[Cites] Cell. 1997 Jun 27;89(7):1033-41 [9215626.001]

[Cites] Immunity. 1997 Jul;7(1):147-54 [9252127.001]

[Cites] Immunity. 1999 Mar;10(3):323-32 [10204488.001]

[Cites] Annu Rev Immunol. 1999;17:781-828 [10358774.001]

[Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]

[Cites] J Exp Med. 2005 Feb 21;201(4):603-14 [15728238.001]

[Cites] Semin Immunol. 2005 Jun;17(3):183-91 [15826823.001]

[Cites] J Immunol. 2005 Jun 1;174(11):6967-73 [15905539.001]

[Cites] Genes Dev. 2005 Jun 1;19(11):1294-305 [15901672.001]

[Cites] Cell Res. 2005 Oct;15(10):749-69 [16246265.001]

[Cites] J Exp Med. 2005 Dec 5;202(11):1471-6 [16314438.001]

[Cites] Blood. 2007 Feb 15;109(4):1620-6 [17062731.001]

[Cites] J Exp Med. 2007 Jul 9;204(7):1665-75 [17591857.001]

[Cites] J Exp Med. 2007 Oct 29;204(11):2513-20 [17908937.001]

[Cites] Science. 1999 Nov 26;286(5445):1735-8 [10576740.001]

[Cites] Nature. 1999 Nov 18;402(6759):255-62 [10580495.001]

[Cites] Genes Dev. 2000 Jan 1;14(1):23-7 [10640272.001]

[Cites] J Immunol. 2000 Apr 15;164(8):3950-4 [10754284.001]

[Cites] J Immunol. 2001 Jan 15;166(2):795-9 [11145652.001]

[Cites] Immunity. 2001 Nov;15(5):763-74 [11728338.001]

[Cites] Immunity. 2002 Jun;16(6):759-67 [12121658.001]

[Cites] Science. 2003 Nov 7;302(5647):1036-8 [14500851.001]

[Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]

[Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):179-88 [14996502.001]

[Cites] J Immunol. 1993 Sep 1;151(5):2546-54 [8360476.001]

(PMID = 18566418.001).

[ISSN] 0022-1767

[Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)

[ISO-abbreviation] J. Immunol.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / R01 AI074754; United States / NIAID NIH HHS / AI / AI054658-05; United States / NCI NIH HHS / CA / R01 CA092123; United States / NCI NIH HHS / CA / CA092123-05; United States / NIAID NIH HHS / AI / R01 AI054658-05; United States / NIAID NIH HHS / AI / AI54683; United States / NCI NIH HHS / CA / R01 CA092123-05; United States / NCI NIH HHS / CA / CA92123; United States / NIAID NIH HHS / AI / R01 AI054658

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein

[Other-IDs] NLM/ NIHMS66462; NLM/ PMC2561902

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Work in Dr. Look's laboratory focuses on the molecular pathogenesis of leukemia.

His group has been credited with the identification and functional analysis of several chimeric oncogenes activated by chromosomal translocations, including the E2A-HLF transcription factor, which was shown to act through an evolutionarily conserved genetic pathway to promote leukemia cell survival.

Their efforts in human T-cell acute lymphoblastic leukemia have revealed key multistep mutational pathways that drive the pathogenesis of this disease and demonstrated that NOTCH1 receptors are mutationally activated in a majority of these cases.

Look's laboratory developed the first transgenic model of leukemia in the zebrafish, opening the way for chemical and genome-wide genetic modifier screens in a vertebrate disease model.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18248181.001).

[ISSN] 1557-8542

[Journal-full-title] Zebrafish

[ISO-abbreviation] Zebrafish

[Language] eng

[Publication-type] Interview

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell.

Hemangioblastomas are central nervous system (CNS) tumors of unknown histogenesis, which can occur sporadically or in von Hippel-Lindau disease.

Failure to specify the cytologic origin of the stromal cell has precluded the development of nonsurgical therapies and limits understanding of its basic biology.

We report that the stromal cells express proteins (Scl, brachyury, Csf-1R, Gata-1, Flk-1, and Tie-2) that characterize embryonic progenitor cells with hemangioblastic differentiation potential and conclude that embryonic progenitors with hemangioblast potential represent a possible cytologic equivalent of the stromal cell.

MedlinePlus Health Information. consumer health - Stem Cells.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16618738.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Angiopoietin-1; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Brachyury protein; 0 / Fetal Proteins; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Proto-Oncogene Proteins; 0 / T-Box Domain Proteins; 135471-20-4 / TAL1 protein, human; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor; EC 2.7.10.1 / Receptor, TIE-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment.

Methotrexate (MTX) is a key drug in the chemotherapy for childhood acute lymphocytic leukemia (ALL).

[MeSH-major] Acute Kidney Injury / chemically induced. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18045317.001).

[ISSN] 1328-8067

[Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society

[ISO-abbreviation] Pediatr Int

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands.

OBJECTIVE: Enteropathy-associated T-cell lymphomas (EATLs) are T-cell non-Hodgkin lymphomas of the small bowel, which are specifically associated with coeliac disease (CD).

We included all T-cell lymphomas detected between January 2000 and December 2006 that initially presented in the small bowel.

Finally, the distribution of characteristics such as the localization, the Marsh classification and method of diagnosis are described.

Most EATLs were localized in the proximal small intestine and the diagnosis was made by surgical resection in the majority of cases.

CONCLUSIONS: EATL is a rare disease with an incidence of 0.10 per 100,000 inhabitants per year, occurring in older age, with a peak incidence in the 7th decade.

[MeSH-major] Celiac Disease / epidemiology. Lymphoma, T-Cell / epidemiology

Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.

MedlinePlus Health Information. consumer health - Celiac Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18618372.001).

[ISSN] 1502-7708

[Journal-full-title] Scandinavian journal of gastroenterology

[ISO-abbreviation] Scand. J. Gastroenterol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Norway

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] How I treat acute and chronic leukemia in pregnancy.

The prevalence of pregnancy associated leukemia is approximately 1 case out of 10,000 pregnancies.

The treatment of a pregnant woman with leukemia may be associated with severe adverse fetal outcome including death and malformations, and therefore poses a difficult challenge for both the patient and the attending physician.

When acute leukemia is diagnosed during the 1st trimester, patients should be treated promptly similar to non-pregnant patients.

When the diagnosis is made later in pregnancy standard chemotherapy regimen should be considered and usually pregnancy termination is not mandatory.

Pregnancy associated chronic myelogenous leukemia (CML) can be treated with interferon throughout pregnancy with no apparent increase in adverse fetal outcome.

In the very rare case of chronic lymphocytic leukemia (CLL) during pregnancy treatment can usually be delayed until after delivery.

[MeSH-major] Antineoplastic Agents / adverse effects. Leukemia / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Prenatal Exposure Delayed Effects

Genetic Alliance. consumer health - Pregnancy.

MedlinePlus Health Information. consumer health - Childhood Leukemia.

MedlinePlus Health Information. consumer health - Leukemia.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for chronic leukemia .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18472198.001).

[ISSN] 0268-960X

[Journal-full-title] Blood reviews

[ISO-abbreviation] Blood Rev.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Scotland

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 111

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TCF1 and beta-catenin regulate T cell development and function.

T cell factor-1 (TCF1) critically regulates T cell development.

We have genetically manipulated the beta-catenin gene and generated mutant mice that have shown an essential role for beta-catenin and TCF1 during pre-T cell receptor (TCR) and TCR-dependent stages of T cell development.

[MeSH-major] Cell Differentiation. Gene Expression Regulation. T Cell Transcription Factor 1 / metabolism. T-Lymphocytes / cytology. T-Lymphocytes / immunology. beta Catenin / metabolism

[MeSH-minor] Animals. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Humans. Mice. Receptors, Antigen, T-Cell / genetics. Receptors, Antigen, T-Cell / metabolism. Signal Transduction

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 2009 Jul;15(7):808-13 [19525962.001]

[Cites] Nat Immunol. 2009 Sep;10(9):992-9 [19648923.001]

[Cites] J Immunol. 2009 Sep 15;183(6):3873-84 [19717519.001]

[Cites] Cell. 1994 Jan 28;76(2):229-39 [8293461.001]

[Cites] Genes Dev. 2000 Jul 15;14(14):1693-711 [10898785.001]

[Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]

[Cites] Eur J Immunol. 2001 Jan;31(1):285-93 [11265645.001]

[Cites] Nat Immunol. 2001 Aug;2(8):691-7 [11477404.001]

[Cites] Nat Immunol. 2001 Sep;2(9):863-9 [11526403.001]

[Cites] Eur J Immunol. 2002 Apr;32(4):967-71 [11920562.001]

[Cites] J Immunol. 2002 May 1;168(9):4268-71 [11970965.001]

[Cites] Nat Rev Immunol. 2002 May;2(5):309-22 [12033737.001]

[Cites] Mol Cell. 2002 Sep;10(3):563-71 [12408824.001]

[Cites] Mol Cell. 2002 Sep;10(3):573-84 [12408825.001]

[Cites] Nat Rev Immunol. 2002 Dec;2(12):933-44 [12461566.001]

[Cites] J Exp Med. 2003 Feb 17;197(4):475-87 [12591905.001]

[Cites] Eur J Immunol. 2003 Jan;33(1):12-8 [12594827.001]

[Cites] Annu Rev Immunol. 2003;21:139-76 [12414722.001]

[Cites] Nat Immunol. 2003 Dec;4(12):1177-82 [14608382.001]

[Cites] Int Immunol. 2003 Dec;15(12):1485-94 [14645157.001]

[Cites] J Exp Med. 2004 Jan 19;199(2):221-9 [14718516.001]

[Cites] Am J Physiol Cell Physiol. 2004 Apr;286(4):C747-56 [14613891.001]

[Cites] Nat Rev Immunol. 2004 Jul;4(7):529-40 [15229472.001]

[Cites] EMBO J. 1991 Jan;10(1):123-32 [1989880.001]

[Cites] J Exp Med. 1994 Apr 1;179(4):1349-53 [8145047.001]

[Cites] J Immunol. 1994 Jul 1;153(1):53-62 [8207255.001]

[Cites] Immunol Today. 1994 Aug;15(8):362-6 [7916949.001]

[Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]

[Cites] Annu Rev Immunol. 1995;13:93-126 [7612239.001]

[Cites] Curr Opin Immunol. 1995 Apr;7(2):188-95 [7546378.001]

[Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]

[Cites] Mol Cell Biol. 1998 Jun;18(6):3495-501 [9584189.001]

[Cites] J Immunol. 1998 Oct 15;161(8):3984-91 [9780167.001]

[Cites] Nature. 1998 Oct 8;395(6702):608-12 [9783587.001]

[Cites] Curr Opin Genet Dev. 1999 Feb;9(1):15-21 [10072352.001]

[Cites] Int Immunol. 1999 Mar;11(3):317-23 [10221643.001]

[Cites] Mol Cell Biol. 1999 Jun;19(6):4503-15 [10330189.001]

[Cites] Nat Immunol. 2005 Aug;6(8):800-9 [16025118.001]

[Cites] J Immunol. 2005 Dec 15;175(12):7981-8 [16339534.001]

[Cites] Immunol Rev. 2006 Feb;209:159-69 [16448541.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3322-6 [16492759.001]

[Cites] Annu Rev Immunol. 2006;24:607-56 [16551261.001]

[Cites] J Immunol. 2006 Apr 15;176(8):4880-7 [16585583.001]

[Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]

[Cites] Immunol Res. 2006;34(2):117-32 [16760572.001]

[Cites] Scand J Immunol. 2006 Aug;64(2):93-6 [16867153.001]

[Cites] Eur J Immunol. 2006 Sep;36(9):2376-83 [16897815.001]

[Cites] Immunity. 2007 Feb;26(2):227-39 [17306568.001]

[Cites] J Immunol. 2007 Apr 15;178(8):5028-34 [17404285.001]

[Cites] Curr Opin Immunol. 2007 Jun;19(3):281-6 [17433650.001]

[Cites] Blood. 2007 Jun 15;109(12):5463-72 [17317856.001]

[Cites] J Immunol. 2007 Jul 1;179(1):126-31 [17579030.001]

[Cites] Cancer Cell. 2007 Dec;12(6):528-41 [18068630.001]

[Cites] Cell. 2007 Dec 14;131(6):1204 [18083108.001]

[Cites] Blood. 2008 Jan 1;111(1):160-4 [17855627.001]

[Cites] Blood. 2008 Jan 1;111(1):142-9 [17906078.001]

[Cites] Nat Med. 2008 Feb;14(2):162-9 [18246080.001]

[Cites] Mol Cell Biol. 2008 Mar;28(5):1713-23 [18160717.001]

[Cites] Immunity. 2008 Apr;28(4):445-53 [18400187.001]

[Cites] Int Immunol. 2008 Jul;20(7):925-35 [18511409.001]

[Cites] Nat Rev Immunol. 2008 Aug;8(8):581-93 [18617885.001]

[Cites] Nat Rev Immunol. 2008 Oct;8(10):788-801 [18802443.001]

[Cites] J Immunol. 2009 Jan 15;182(2):751-8 [19124717.001]

[Cites] J Immunol. 2009 Jan 15;182(2):759-65 [19124718.001]

[Cites] Blood. 2009 Jan 15;113(3):546-54 [18832654.001]

[Cites] Curr Opin Immunol. 2009 Jun;21(3):274-80 [19524429.001]

(PMID = 20082155.001).

[ISSN] 1559-0755

[Journal-full-title] Immunologic research

[ISO-abbreviation] Immunol. Res.

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 AG000768-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; 0 / T Cell Transcription Factor 1; 0 / beta Catenin

[Other-IDs] NLM/ NIHMS172600; NLM/ PMC2891409

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Nkx2.5 is a homeodomain-containing nuclear transcription protein that has been associated with acute T-lymphoblastic leukemia.

In addition, the expression of Nkx2.5 was significantly increased in psoriasis and squamous cell carcinoma, but was barely detected in atopic dermatitis and basal cell carcinoma.

CONCLUSION: These results suggest that Nkx2.5 may play a role in the change from proliferation to differentiation of keratinocytes and in the pathogenesis of skin disease with aberrant keratinocyte differentiation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Exp Mol Med. 1999 Mar 31;31(1):5-19 [10231017.001]

[Cites] J Cell Sci Suppl. 1993;17:197-208 [7511614.001]

[Cites] Cancer Res. 2003 Sep 1;63(17):5329-34 [14500364.001]

[Cites] J Am Coll Cardiol. 2003 Nov 5;42(9):1650-5 [14607454.001]

[Cites] Mol Cell Biol. 2003 Dec;23(24):9222-32 [14645532.001]

[Cites] Gene Expr Patterns. 2004 Nov;5(1):129-34 [15533828.001]

[Cites] Pharmacol Ther. 2005 Aug;107(2):252-68 [15925411.001]

[Cites] Haematologica. 2006 Mar;91(3):317-21 [16531254.001]

[Cites] J Rheumatol. 2006 Nov;33(11):2167-72 [16981296.001]

[Cites] Arch Med Res. 2007 Jan;38(1):64-9 [17174725.001]

[Cites] Br J Dermatol. 2007 Feb;156(2):271-6 [17223866.001]

[Cites] Cell. 1977 Jun;11(2):417-22 [890737.001]

[Cites] PLoS One. 2008;3(6):e2301 [18523683.001]

[Cites] J Biol Chem. 1995 Jul 28;270(30):17702-11 [7543090.001]

[Cites] Dev Biol. 1996 Sep 15;178(2):203-16 [8812123.001]

[Cites] J Biol Chem. 1997 Jan 17;272(3):2021-30 [8999895.001]

[Cites] Cancer Res. 2007 Feb 15;67(4):1461-71 [17308084.001]

[Cites] J Am Acad Dermatol. 2007 Aug;57(2):347-54 [17433490.001]

[Cites] Bioessays. 2002 Sep;24(9):789-800 [12210515.001]

(PMID = 20523827.001).

[ISSN] 2005-3894

[Journal-full-title] Annals of dermatology

[ISO-abbreviation] Ann Dermatol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC2861273

[Keywords] NOTNLM ; Keratinocyte differentiation / Nkx2.5 / Transcription factor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review.

Therapy-related acute lymphoblastic leukemia (t-ALL) is a rare secondary leukemia following chemotherapy and/or radiotherapy for primary malignancies.

Chromosomal 11q23 abnormality, frequently detected in therapy-related acute myeloid leukemia, is the most common cytogenetic alteration in t-ALL.

However, t-ALL cases without 11q23 abnormality have been rarely described.

In the 48 cases, an 11q23 abnormality involving the MLL gene locus was the predominant chromosomal aberration (32 [67%]), followed by t(9;22) (6 [13%]) and a normal karyotype (4 [8%]).

Compared with t-ALL cases with an 11q23 abnormality, cases without an 11q23 abnormality had a relatively longer latency period (median, 36 vs 19 months) and a different primary malignancy spectrum.

The t(8;14)(q11.2;q32), a rare, nonrandom, balanced chromosomal translocation differing from the more common translocation involving c-MYC on chromosome 8q24, was seen in 1 adult t-ALL case, which may suggest another possible pathogenesis of this disease.

[MeSH-major] Chromosomes, Human, Pair 11. Combined Modality Therapy / adverse effects. Neoplasms / therapy. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20023261.001).

[ISSN] 1943-7722

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 42

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An improved methodology to detect human T cell receptor beta variable family gene expression patterns.

Comprehensive gene expression analysis of the T cell receptor repertoire of an individual can be very useful in evaluating the immune response in a variety of conditions.

Antibody-based analysis methods can detect approximately 60% of the human T cell receptor beta variable (TCRBV) proteins, while gene expression analysis, primarily through employment of the polymerase chain reaction (PCR), has had somewhat greater success in the detection of additional TCRBV families.

We describe here a real-time reverse transcription polymerase chain reaction-based method, which allows efficient automation and integration of amplification, detection, and analysis with sequence-specific detection of all T cell receptor beta variable gene families, subfamilies, and alleles.

[MeSH-major] Gene Expression Profiling / methods. Multigene Family. Receptors, Antigen, T-Cell, alpha-beta / biosynthesis. Receptors, Antigen, T-Cell, alpha-beta / genetics

[MeSH-minor] DNA Primers. Fluorometry / methods. Genetic Variation. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / metabolism. Humans. Polymerase Chain Reaction / methods. RNA, Messenger / biosynthesis

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16038929.001).

[ISSN] 0022-1759

[Journal-full-title] Journal of immunological methods

[ISO-abbreviation] J. Immunol. Methods

[Language] eng

[Grant] United States / NCRR NIH HHS / RR / 5 P20 RR16440-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] Netherlands

[Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell, alpha-beta

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Multiple tumor cell lines of varying histiotypes, including A549 (lung adenocarcinoma), 786-O (renal cell carcinoma), HeLa (cervical carcinoma), MDA-MB-231 (breast), K562 (chronic myelogenous leukemia), Jurkat (acute T-cell leukemia), MEC-2 (B-chronic lymphocytic leukemia), and U251 and D37 (glioma), as well as cells derived from primary human glioma tumors that are likely a more clinically relevant model were treated with sorafenib or bortezomib alone or in combination.

Sorafenib and bortezomib synergistically induced a marked increase in mitochondrial injury and apoptosis, reflected by cytochrome c release, caspase-3 cleavage, and poly(ADP-ribose) polymerase degradation in a broad range of solid tumor and leukemia cell lines.

These findings were accompanied by several biochemical changes, including decreased phosphorylation of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor-beta, and Akt and increased phosphorylation of stress-related c-Jun NH2-terminal kinase (JNK).

These findings show that sorafenib interacts synergistically with bortezomib to induce apoptosis in a broad spectrum of neoplastic cell lines and show an important role for the Akt and JNK pathways in mediating synergism.

[MeSH-minor] Antineoplastic Agents / pharmacology. Bortezomib. Cell Line, Tumor. Drug Synergism. Humans. Jurkat Cells. K562 Cells. MAP Kinase Signaling System / drug effects. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proteasome Endopeptidase Complex / metabolism

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BORTEZOMIB .

Hazardous Substances Data Bank. NICOTINAMIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16985072.001).

[ISSN] 1535-7163

[Journal-full-title] Molecular cancer therapeutics

[ISO-abbreviation] Mol. Cancer Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Boronic Acids; 0 / Phenylurea Compounds; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 69G8BD63PP / Bortezomib; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?

OBJECTIVE: Cortical lesions in multiple sclerosis (MS) are notoriously difficult to visualize with standard MR imaging (MRI) techniques.

However, the use of higher field-strengths with intrinsically higher signal-to-noise, which can partly be used to increase spatial resolution, may improve cortical lesion detection.

Therefore, in this post mortem study, the sensitivity of high field-strength MRI (4.7 T) for cortical lesions was investigated, and compared to that of standard field-strength (1.5 T).

Proteolipid protein (PLP)-stained tissue sections (10 microm) of the same brain slices were matched to the corresponding MR images, and cortical lesions were scored on all three MR sequences (blinded to histology) and in tissue sections (blinded to MRI).

Sensitivity of the sequences for four cortical lesion types was calculated.

RESULTS: Sensitivity for purely intracortical lesions (histological lesion types II, III, and IV; n = 128) was below 10 % for both 1.5 T and 4.7 T MRI, while mixed gray matter-white matter (type I) lesions (n = 5) were detected in four out of five cases.

CONCLUSIONS: MRI sensitivity for post mortem detection of cortical lesions is low, even when a higher field-strength was used.

It varies, however, for different subtypes of cortical lesions.

Genetic Alliance. consumer health - Multiple Sclerosis.

MedlinePlus Health Information. consumer health - Multiple Sclerosis.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FORMALDEHYDE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Brain. 2004 May;127(Pt 5):1101-7 [14998914.001]

[Cites] J Neurol Neurosurg Psychiatry. 1962 Nov;25:315-20 [14016083.001]

[Cites] Neurology. 2003 Apr 8;60(7):1157-62 [12682324.001]

[Cites] Ital J Neurol Sci. 1992 Dec;13(9 Suppl 14):97-103 [1345748.001]

[Cites] Arch Neurol. 2007 Jan;64(1):76-80 [17210812.001]

[Cites] Neurology. 2004 Feb 24;62(4):586-90 [14981175.001]

[Cites] Mult Scler. 2003 Aug;9(4):323-31 [12926836.001]

[Cites] Ann Neurol. 2001 Jul;50(1):121-7 [11456302.001]

[Cites] Brain. 2001 Aug;124(Pt 8):1635-45 [11459754.001]

[Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):106-17 [15043708.001]

[Cites] J Neurol Sci. 1987 Oct;81(1):67-77 [3681342.001]

[Cites] AJNR Am J Neuroradiol. 2005 Mar;26(3):572-7 [15760868.001]

[Cites] AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1956-62 [10588125.001]

[Cites] Ann Neurol. 2001 Sep;50(3):389-400 [11558796.001]

[Cites] Mult Scler. 2000 Aug;6(4):280-5 [10962549.001]

[Cites] Brain. 2005 Nov;128(Pt 11):2705-12 [16230320.001]

[Cites] Neurology. 2006 Sep 26;67(6):960-7 [17000961.001]

[Cites] Acta Radiol. 1999 Nov;40(6):593-7 [10598845.001]

[Cites] Epilepsia. 2001 Jan;42(1):72-9 [11207788.001]

[Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1101-7 [16319720.001]

[Cites] J Neuropathol Exp Neurol. 2005 Feb;64(2):147-55 [15751229.001]

[Cites] AJNR Am J Neuroradiol. 2001 Mar;22(3):470-5 [11237968.001]

[Cites] Curr Opin Neurol. 2002 Jun;15(3):239-45 [12045719.001]

[Cites] Med Phys. 1985 Mar-Apr;12(2):232-3 [4000083.001]

[Cites] J Neuropathol Exp Neurol. 2003 Jul;62(7):723-32 [12901699.001]

[Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):985-8 [12063230.001]

[Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):402-8 [10696031.001]

[Cites] Radiology. 2005 Jul;236(1):254-60 [15987979.001]

[Cites] J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):998-1002 [15201359.001]

[Cites] Ann Neurol. 2004 Sep;56(3):407-15 [15349868.001]

[Cites] Neurobiol Dis. 2005 Dec;20(3):953-60 [16039866.001]

[Cites] AJNR Am J Neuroradiol. 2005 Aug;26(7):1824-31 [16091537.001]

[Cites] Acta Neurol Scand Suppl. 2006;183:48-50 [16637929.001]

[Cites] J Magn Reson Imaging. 2006 May;23(5):628-36 [16565955.001]

[Cites] J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):311-7 [11181851.001]

[Cites] Brain. 1997 Nov;120 ( Pt 11):2059-69 [9397021.001]

(PMID = 18231704.001).

[ISSN] 0340-5354

[Journal-full-title] Journal of neurology

[ISO-abbreviation] J. Neurol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Fixatives; 1HG84L3525 / Formaldehyde

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death.

Q(2 )induced cell death in leukemia, myeloma, and solid tumor cell lines with LD50s in the low to submicromolar range.

Moreover, Q(2) induced cell death in primary acute myeloid leukemia (AML) cells preferentially over normal hematopoietic cells.

In a mouse model of leukemia, Q(2) delayed tumor growth.

Mechanistically, Q(2) induced cell death through caspase independent mechanisms.

Potentially consistent with the induction of autophagic cell death, Q(2) treatment led to a punctate distribution of LC3 and increased MDC staining.

Thus, Q(2) is a novel quinolinium with preclinical activity in malignancies such as leukemia and myeloma and warrants further investigation.

[MeSH-major] Cell Death / drug effects. Quinolinium Compounds / pharmacology

[MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Animals. Autophagy / drug effects. Caspases / physiology. Cell Line, Tumor. Cell Survival / drug effects. HeLa Cells. Humans. Jurkat Cells. Lethal Dose 50. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Mice. Mice, Inbred DBA. Tumor Cells, Cultured. U937 Cells

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18415680.001).

[ISSN] 1573-675X

[Journal-full-title] Apoptosis : an international journal on programmed cell death

[ISO-abbreviation] Apoptosis

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / 1-methyl-2-(3-(1-methyl-1,2-dihydroquinolin-2-yliden)prop-1-enyl)quinolinium iodide; 0 / Amino Acid Chloromethyl Ketones; 0 / Quinolinium Compounds; 0 / benzyloxycarbonyltyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone; EC 3.4.22.- / Caspases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Consistent with this, the early pulse of SCL expression also expanded hematopoietic colony-forming cell numbers, while concomitantly repressing expression of paraxial and cardiac markers, and inhibited development of beating cardiomyocytes.

By mixing the inducible embryonic stem cells with fluorescently labeled wild-type cells in chimeric embryoid bodies, we show that these effects of SCL are cell autonomous.

[MeSH-minor] Animals. Antigens, Differentiation / biosynthesis. Antigens, Differentiation / genetics. Cell Line. Colony-Forming Units Assay. Endothelium, Vascular / cytology. Endothelium, Vascular / embryology. Mice. Myocytes, Cardiac / cytology. Myocytes, Cardiac / metabolism. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Time Factors. Transgenes / physiology. Vascular Endothelial Growth Factor Receptor-2 / genetics. Vascular Endothelial Growth Factor Receptor-2 / metabolism

MedlinePlus Health Information. consumer health - Stem Cells.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18809240.001).

[ISSN] 0301-472X

[Journal-full-title] Experimental hematology

[ISO-abbreviation] Exp. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To characterize how interleukin-3 and erythropoietin regulate cell fate by modulating the expression of lineage-specific transcription factors.

METHODS: This study analyzed mRNA and protein levels, gene transcription rates, and mRNA and protein stabilities of erythroid-specific transcription factors in lineage-restricted cells derived from the 32D cell line cultured either in interleukin-3 or erythropoietin.

Switching the erythroid cells to erythropoietin induced cell maturation (within 48 hours) and reduced expression of Gata-2 and Idl (in 24 hours) but did not alter the expression of Gata-1.

[MeSH-minor] Animals. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Line. Gene Expression Profiling. Mice. Phenotype. RNA, Messenger / drug effects. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Structure-Activity Relationship. T-Cell Acute Lymphocytic Leukemia Protein 1. Time Factors

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17577923.001).

[ISSN] 0301-472X

[Journal-full-title] Experimental hematology

[ISO-abbreviation] Exp. Hematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01-CA108671-01A2

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Erythroid-Specific DNA-Binding Factors; 0 / Idb1 protein, mouse; 0 / Inhibitor of Differentiation Protein 1; 0 / Interleukin-3; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / T-Cell Acute Lymphocytic Leukemia Protein 1; 0 / Tal1 protein, mouse; 11096-26-7 / Erythropoietin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The molecular mechanisms involved in disease progression and relapse in T-cell acute lymphoblastic leukemia (T-ALL) are poorly understood.

This analysis showed that diagnosis and relapsed cases have common genetic alterations, but also that relapsed samples frequently lose chromosomal markers present at diagnosis, suggesting that relapsed T-ALL emerges from an ancestral clone different from the major leukemic population at diagnosis.

[MeSH-major] Genes, Wilms Tumor. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

[MeSH-minor] Adult. Child. Chromosome Aberrations. Clone Cells / chemistry. DNA Methylation. DNA Mutational Analysis. DNA, Neoplasm / genetics. Disease Progression. Genes, Homeobox. Humans. Kaplan-Meier Estimate. Neoplasm Proteins / chemistry. Neoplasm Proteins / genetics. Oncogenes. Polymorphism, Single Nucleotide. Prognosis. Recurrence. WT1 Proteins / chemistry. WT1 Proteins / genetics. Zinc Fingers / genetics

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6010-4 [1321431.001]

[Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]

[Cites] Hum Mol Genet. 1993 Mar;2(3):259-64 [8388765.001]

[Cites] Blood. 1994 May 15;83(10):2922-30 [8180387.001]

[Cites] Hum Mol Genet. 1995 Mar;4(3):351-8 [7795587.001]

[Cites] Blood. 1996 Mar 15;87(6):2171-9 [8630376.001]

[Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]

[Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]

[Cites] Eur J Haematol. 1997 May;58(5):346-9 [9222290.001]

[Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]

[Cites] Kidney Int. 1998 Jun;53(6):1512-8 [9607183.001]

[Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]

[Cites] Pediatr Blood Cancer. 2006 Jan;46(1):18-25 [15929133.001]

[Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]

[Cites] Haematologica. 2006 Sep;91(9):1212-21 [16956820.001]

[Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]

[Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]

[Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]

[Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]

[Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]

[Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]

[Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]

[Cites] Cancer Res. 2007 Oct 1;67(19):9006-12 [17909001.001]

[Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]

[Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]

[Cites] J Exp Med. 2007 Dec 24;204(13):3059-66 [18070937.001]

[Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]

[Cites] Nat Rev Cancer. 2008 Feb;8(2):83-93 [18094723.001]

[Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]

[Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]

[Cites] Nat Rev Immunol. 2008 May;8(5):380-90 [18421304.001]

[Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]

[Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]

[Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]

[Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]

[Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]

[Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]

[Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]

[Cites] Genome Biol. 2001;2(8):RESEARCH0032 [11532216.001]

[Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]

[Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):416-9 [11878574.001]

[Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]

[Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]

[Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]

[Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]

[Cites] Clin Nephrol. 1985 Dec;24(6):269-78 [3000666.001]

[Cites] Genomics. 1989 Nov;5(4):685-93 [2556343.001]

[Cites] Cell. 1990 Jun 29;61(7):1257-69 [2163761.001]

[Cites] FEBS Lett. 1993 Feb 8;317(1-2):39-43 [8381368.001]

(PMID = 19494353.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Databank-accession-numbers] GEO/ GSE15931

[Grant] United States / NCI NIH HHS / CA / CA114737; United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / CA02111; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / WT1 Proteins

[Other-IDs] NLM/ PMC2721784

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique.

In order to gain additional clinico-hematological data and to identify new partners of NUP98, the Groupe Francophone de Cytogénétique Hématologique (GFCH) collected cases of hematological malignancies where a 11p15 rearrangement was detected.

Genes of the HOXA cluster and the nuclear-receptor set domain (NSD) genes were frequently fused to NUP98, mainly in de novo myeloid malignancies whereas the DDX10 and TOP1 genes were equally rearranged in de novo and in therapy-related myeloid proliferations.

Involvement of ADD3 and C6ORF80 genes were detected, respectively, in myeloid disorders and in T-cell acute lymphoblastic leukemia (T-ALL), whereas the RAP1GDS1 gene was fused to NUP98 in T-ALL.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. HGNC: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16467868.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; 0 / Receptors, Cytoplasmic and Nuclear; 157907-48-7 / HoxA protein

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.

BCR-ABL plays an essential role in the pathogenesis of chronic myeloid leukemia (CML) and some cases of acute lymphocytic leukemia (ALL).

Although ABL kinase inhibitors have shown great promise in the treatment of CML, the persistence of residual disease and the occurrence of resistance have prompted investigations into the molecular effectors of BCR-ABL.

As several downstream mediators of BCR-ABL are regulated by the proteasome degradation pathway, we also show that inhibition of this pathway, using bortezomib, causes regression of CML-like disease.

Our data delineate the involvement of FoxO proteins in BCR-ABL-induced evasion of apoptosis and provide evidence that bortezomib is a candidate therapeutic in the treatment of BCR-ABL-induced leukemia.

MedlinePlus Health Information. consumer health - Leukemia.

Hazardous Substances Data Bank. BORTEZOMIB .

Hazardous Substances Data Bank. IMATINIB MESYLATE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] EMBO J. 1997 Oct 15;16(20):6151-61 [9321394.001]

[Cites] Blood. 1995 Jul 15;86(2):726-36 [7606002.001]

[Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]

[Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421-6 [10377430.001]

[Cites] Haematologica. 2004 Dec;89(12):1428-33 [15590391.001]

[Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]

[Cites] Cancer Cell. 2005 Feb;7(2):129-41 [15710326.001]

[Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]

[Cites] Cancer Cell. 2005 Mar;7(3):227-38 [15766661.001]

[Cites] Oncogene. 2005 Mar 31;24(14):2317-29 [15688014.001]

[Cites] Mol Cancer Ther. 2005 Apr;4(4):686-92 [15827343.001]

[Cites] Blood. 2005 May 15;105(10):4021-7 [15665113.001]

[Cites] J Immunol. 2006 Apr 15;176(8):4757-65 [16585569.001]

[Cites] J Immunol. 2006 May 15;176(10):6302-12 [16670342.001]

[Cites] Blood. 2006 May 15;107(10):4063-70 [16424391.001]

[Cites] Cancer Res. 2006 Jun 15;66(12):6304-11 [16778207.001]

[Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]

[Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]

[Cites] Nat Rev Cancer. 2007 May;7(5):345-56 [17457302.001]

[Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50 [17522590.001]

[Cites] Blood. 2007 Jul 1;110(1):345-53 [17374740.001]

[Cites] Curr Oncol Rep. 2007 Sep;9(5):391-8 [17706168.001]

[Cites] Oncology (Williston Park). 2007 Jun;21(7):785-92; discussion 798-800 [17722741.001]

[Cites] J Clin Invest. 2007 Sep;117(9):2562-9 [17710227.001]

[Cites] Acta Physiol (Oxf). 2008 Jan;192(1):19-28 [18171426.001]

[Cites] Expert Opin Investig Drugs. 2008 Jun;17(6):865-78 [18491988.001]

[Cites] Blood. 1997 Dec 15;90(12):4947-52 [9389713.001]

[Cites] Mol Cell Biol. 2000 Feb;20(4):1179-86 [10648603.001]

[Cites] Curr Biol. 2000 Oct 5;10(19):1201-4 [11050388.001]

[Cites] Blood. 2000 Nov 15;96(10):3343-56 [11071626.001]

[Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]

[Cites] Curr Oncol Rep. 2001 May;3(3):228-37 [11296133.001]

[Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]

[Cites] Blood. 2001 Nov 15;98(10):2948-57 [11698276.001]

[Cites] Semin Oncol. 2001 Dec;28(6):613-9 [11740819.001]

[Cites] Trends Mol Med. 2002;8(4 Suppl):S49-54 [11927288.001]

[Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]

[Cites] J Biol Chem. 2002 Dec 6;277(49):47928-37 [12351634.001]

[Cites] J Biol Chem. 2003 Apr 4;278(14):12361-6 [12517744.001]

[Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6523-8 [12750477.001]

[Cites] J Cell Biol. 2003 Aug 18;162(4):613-22 [12913110.001]

[Cites] J Biol Chem. 2003 Sep 19;278(38):35959-67 [12857750.001]

[Cites] Leuk Res. 2004 May;28 Suppl 1:S21-8 [15036938.001]

[Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]

[Cites] Oncogene. 2004 Apr 22;23(19):3338-49 [14981546.001]

[Cites] Blood. 2004 Jun 15;103(12):4622-9 [14962911.001]

[Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]

[Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]

[Cites] Mol Cell Biol. 1991 Feb;11(2):1107-13 [1846663.001]

[ErratumIn] Cancer Res. 2009 Sep 1;69(17):7130. Rodin, Heather Yeckes [corrected to Yeckes-Rodin, Heather]

(PMID = 19654305.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NHLBI NIH HHS / HL / HL080192-05; United States / NHLBI NIH HHS / HL / HL080192; United States / NHLBI NIH HHS / HL / R01 HL080192; United States / NCI NIH HHS / CA / R01 CA131664; United States / NHLBI NIH HHS / HL / R01 HL080192-05; United States / NCI NIH HHS / CA / P30CA6516; United States / NCI NIH HHS / CA / R01 CA105306-05; United States / NCI NIH HHS / CA / R01 CA105306; United States / NCI NIH HHS / CA / CA105306; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA105306-05; United States / NCI NIH HHS / CA / CA131664

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Boronic Acids; 0 / Cysteine Proteinase Inhibitors; 0 / Forkhead Transcription Factors; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / Pyrimidines; 0 / Tumor Suppressor Proteins; 69G8BD63PP / Bortezomib; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl

[Other-IDs] NLM/ NIHMS123965; NLM/ PMC2763358